When analyzing the lifecycle of any health care product, a key component to consider is how much the product will cost and who will pay for it. What unique challenges do direct access tests pose when it comes to reimbursement and related compliance requirements? On the second episode of our four-part series on direct access laboratory testing, Epstein Becker Green attorneys Bob Hearn and Megan Robertson and EBG Advisor Dr. Joel Brill discuss coverage and reimbursement for direct access tests, as well as the related compliance factors that labs, product developers, and investors in the diagnostic testing industry should be aware of.

 

Visit our site for related resources and email contact information: https://www.ebglaw.com/dhc59.

 

Subscribe for email notifications: https://www.ebglaw.com/subscribe.

 

Visit: http://diagnosinghealthcare.com.

 

The EMPLOYMENT LAW THIS WEEK® and DIAGNOSING HEALTH CARE podcasts are presented by Epstein Becker & Green, P.C. All rights are reserved. This audio recording includes information about legal issues and legal developments. Such materials are for informational purposes only and may not reflect the most current legal developments. These informational materials are not intended, and should not be taken, as legal advice on any particular set of facts or circumstances, and these materials are not a substitute for the advice of competent counsel. The content reflects the personal views and opinions of the participants. No attorney-client relationship has been created by this audio recording. This audio recording may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules. The determination of the need for legal services and the choice of a lawyer are extremely important decisions and should not be based solely upon advertisements or self-proclaimed expertise. No representation is made that the quality of the legal services to be performed is greater than the quality of legal services performed by other lawyers.